An AstraZeneca drug designed to block tumor growth is now approved as a treatment for neurofibromatosis type 1 (NF1), a rare inherited disorder that leads to tumors on nerves throughout the body.
The FDA’s Friday decision for the drug, selumetinib (Koselugo), makes it the first approved treatment for NF1. It’s also the latest twist in a winding path. The small molecule has been developed under the watch of several companies besides AstraZeneca (NYSE: AZN), and it has been tested in a number of cancers—unsuccessfully in some cases.
NF1 is a nervous system disorder that is typically diagnosed early in childhood…. Read more »
UNDERWRITERS AND PARTNERS
